|
gptkbp:instanceOf
|
gptkb:drug
biguanide
|
|
gptkbp:approvalYear
|
1994
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A10BA02
|
|
gptkbp:bioavailability
|
50-60%
|
|
gptkbp:brand
|
gptkb:Riomet
gptkb:Fortamet
gptkb:Glucophage
gptkb:Glumetza
|
|
gptkbp:CASNumber
|
657-24-9
|
|
gptkbp:chemicalClass
|
biguanide
|
|
gptkbp:contraindication
|
severe renal impairment
metabolic acidosis
hypersensitivity to metformin
|
|
gptkbp:discoveredBy
|
gptkb:James_Bell
gptkb:Emile_Werner
|
|
gptkbp:discoveredIn
|
1922
|
|
gptkbp:drugClass
|
antihyperglycemic agent
|
|
gptkbp:eliminationHalfLife
|
4-8.7 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
gptkb:tablet
oral solution
extended-release tablet
|
|
gptkbp:hasMolecularFormula
|
C4H11N5·HCl
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Metformin HCl
|
|
gptkbp:indication
|
gptkb:polycystic_ovary_syndrome
gptkb:gestational_diabetes
gptkb:prediabetes
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
decreases hepatic glucose production
increases insulin sensitivity
decreases intestinal absorption of glucose
|
|
gptkbp:metabolism
|
not metabolized
|
|
gptkbp:offLabelUse
|
weight loss
anti-aging research
|
|
gptkbp:pregnancyCategory
|
B
|
|
gptkbp:proteinBinding
|
negligible
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
gastrointestinal upset
lactic acidosis
|
|
gptkbp:synonym
|
gptkb:1,1-dimethylbiguanide_hydrochloride
gptkb:dimethylbiguanide_hydrochloride
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:DB00907
|
|
gptkbp:bfsLayer
|
7
|